🇺🇸 FDA

Company profile · Sponsor

ORAMED

ORAMED PHARMACEUTICALS INC.

ORMP · NYSE pharma NEW YORK, NY, USA
Pipeline
14
Drugs
0
Patents
8

Quick answer

ORAMED (ORMP) is a pharma company. headquartered in NEW YORK, NY, USA. listed on NYSE. NovaPharmaNews links 14 pipeline programs, 0 drugs, and 8 patents to this profile..

Company facts

Ticker ORMP
Exchange NYSE
Company type pharma
Headquarters NEW YORK, NY, USA
SEC CIK 0001176309

Pipeline (14)

Search pipeline →

  1. ORMD-0801

    ORAMED

    Diabetes Mellitus, Type 2

    phase 3 small molecule active

    2 trials

  2. ORMD-0801

    ORAMED

    T2DM (Type 2 Diabetes Mellitus)

    phase 3 small molecule terminated

    1 trial

  3. ORMD-0801 (qd)

    ORAMED

    Type 2 Diabetes Mellitus

    phase 3 small molecule completed

    2 trials

  4. ORMD-0801 8 mg

    ORAMED

    Type 2 Diabetes Mellitus

    phase 3 small molecule active

    1 trial

  5. Cohort A: ORMD-0801

    ORAMED

    T2DM (Type 2 Diabetes Mellitus)

    phase 2 small molecule completed

    1 trial

  6. ORMD 0801

    ORAMED

    Brittle Type I Diabetes Mellitus

    phase 2 small molecule completed

    1 trial

  7. ORMD-0801

    ORAMED

    Diabetes Type 2

    phase 2 small molecule completed

    1 trial

  8. ORMD-0801 (Insulin) capsule 8 mg BD

    ORAMED

    Diabetes Mellitus, Type 2

    phase 2 small molecule completed

    1 trial

  9. ORMD-0801 Capsules

    ORAMED

    Diabetes Mellitus Type 1

    phase 2 mab completed

    1 trial

  10. ORMD-0801 Dose # 1

    ORAMED

    Diabetes Mellitus Type 2

    phase 2 small molecule completed

    1 trial

  11. ORMD-0801 QD

    ORAMED

    Nonalcoholic Steatohepatitis (NASH)

    phase 2 small molecule completed

    1 trial

  12. ORMD-0801 Treatment A

    ORAMED

    Type 1 Diabetes

    phase 2 small molecule completed

    1 trial

  13. ORMD-0801 capsules- 2x8mg

    ORAMED

    Type 1 Diabetes

    phase 2 small molecule completed

    1 trial

  14. Oral Insulin

    ORAMED

    Non-Alcoholic Steatohepatitis (NASH)

    phase 2 mab completed

    1 trial

Patents (8)

Search patents →

  1. US 11660327

    Methods and compositions for oral administration of proteins

    Expires Mon May 25 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 11395848

    Methods and compositions for treating diabetes

    Expires Mon Jul 21 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 10967051

    Methods and compositions for treating NAFLD, hepatic steatosis, and sequelae thereof

    Expires Mon Apr 01 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 10933022

    Protease inhibitor-containing compositions, compositions comprising same, and methods for producing and using same

    Expires Mon Feb 25 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 10881714

    Methods and compositions for oral administration of proteins

    Expires Mon Dec 31 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 10398762

    Methods and compositions for treating diabetes

    Expires Mon Aug 29 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 10350162

    Methods and compositions for oral administration of exenatide

    Expires Mon Jul 11 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 10342764

    Protease inhibitor-containing compositions, compositions comprising same, and methods for producing and using same

    Expires Mon Jul 04 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is ORAMED?

ORAMED (ORMP) is a pharma company. headquartered in NEW YORK, NY, USA. listed on NYSE. NovaPharmaNews links 14 pipeline programs, 0 drugs, and 8 patents to this profile..

What pipeline programs does ORAMED sponsor?

We track 14 ClinicalTrials.gov-linked programs for ORAMED, including ORMD-0801 and 13 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does ORAMED company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.